During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...
ROS1 is a rare mutation found in fewer than 2% of NSCLC cases. Currently there is a lack of treatments for ROS1-positive NSCLC, especially for people whose lung cancer has spread to the brain.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback